21 hrs ago | IndyStar.com
Bill reduces proposed fees on medical device makers
The Senate scaled back proposed fees on Eli Lilly and Co., Cook Medical and other makers of medical devices as part of the health-care bill that could get its first test vote today.
Top Eli Lilly researcher Paul's payout: $2M
As struggling Indianapolis drugmaker Eli Lilly and Co. slashes thousands of jobs and trims benefits for employees, one top executive is getting a handsome retirement payout.
Rival: ED drug faster than Viagra, Lilly's Cialis
A drug being developed by a California company was shown in a trial to be effective in 30 minutes or less, much faster than its competitors, the maker of treatments for erectile dysfunctions said today.
No Relief for Genzyme as APB Failure Dents Renal Franchise
Genzyme Corp. is dropping further work on its advanced phosphate binder - the product expected to save the Cambridge, Mass.-based firm's renal franchise from the looming patent cliff - after it failed to show improvement over Renvela in a Phase II/III trial, leaving analysts and investors to wonder what's next for the big biotech, which has ...
Vivus Drug Helps Men Get Erections in 30 Minutes, Faster Than Competitors
Vivus Inc ., an unprofitable biotechnology company, said its experimental impotence drug helped men achieve erections in as little as 30 minutes in a study, or about twice as fast as Pfizera s Inc.a s Viagra.
Biologic drugs could face competition from generics
A fast-growing category of prescription drugs that are among the most expensive on the market could, for the first time, face competition from generic competitors under the health-care bills moving through Congress.
Lilly's big cancer bet: seeking new blockbusters
In a corner of an Eli Lilly and Co. cancer laboratory, biologist Julie Pomeroy squeezes drops of a fluorescent stain onto mice tumor tissues, trying to make their mysterious world more visible under a microscope.
GeneNews announces operational and financial results for the third quarter of 2009
GeneNews Limited , a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today reported operational and financial results for the third quarter-ended September 30, 2009.
PhRMA Proposes FDA-Approved Logo for Marketing in Social Media
PhRMA is advocating for a universal safety symbol -- either the FDA logo itself or an FDA-approved symbol -- to indicate that a Twitter or Facebook mention links to a page that contains the pharmaceutical company's FDA-mandated risk information.
Eli Lilly chief researcher to retire
Eli Lilly & Co. said Friday its science and technology head will retire and that it has hired the chief researcher at AstraZeneca PLC to replace him.
U.S. FDA tackles gray area of social media
Drug makers, Internet companies and nonprofits packed a hearing into what is a gray area for U.S. health regulators: how far Twitter, Wikipedia, blogs and other social media can go in promoting drugs.
Lilly, WellPoint CEOs pin hopes on Senate
After the U.S. House of Representatives narrowly passed a sweeping health care overhaul, leaders of Indiana's two largest health care entities turned their hopes to the U.S. Senate to give them a bill more to their liking.
The following videos are provided by third-parties on behalf of their sponsors. New DocRock music video teaches kids how to avoid H1N1 Produced for CIGNA - DocRock's catchy H1N1 Rap gives kids a memorable way to follow the steps provided by the CDC to avoid contracting the H1N1 flu.
Christel House Academy plans high school for 2010
Christel DeHaan's educational philanthropy has taken her around the globe, building schools for the impoverished in India, Mexico, Venezuela and South Africa.
Glassman Sees `Fine Line' for Off-Label Drug Marketing: Video
Nov. 9 -- Robert Glassman, private equity partner at OrbiMed Advisors, talks with Bloomberg's Erik Schatzker and Deirdre Bolton about the practice of so-called off-label drug marketing and its impact on the industry.
Pharmaceutical giant Eli Lilly opened a new state-of-the-art biotechnology center in San Diego, part of an ongoing effort by the drugmaker to transform itself into a biotech titan.
Residents still await quarry's response
Robert Ravenell spent every morning for two weeks outside the limestone quarry he said put cracks in the bricks of his house.
Amylin Pharmaceuticals got a triple dose of good news over the weekend. Individually, each update might not have amounted to much, but together they were good for a 10% pop in the company's shares yesterday.
S.C. limiting some Medicaid patients to one drugstore
South Carolina, trying to curb abuse of narcotics and save money, is requiring Medicaid patients suspected of doctor-hopping for drugs to choose one pharmacy for all of their prescriptions.
Eli Lilly Laying-Off 191 Employees
Indianapolis-based Eli Lilly plans to layoff 191 salespeople throughout the US by the end of the year.
Also on Topix